AOC-DMD exon 45 skipping program / Eli Lilly, Avidity Biosci, Novartis - LARVOL DELTA

Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia (PRNewswire) - "In 2H 2021, Avidity plans to initiate a Phase 1/2 clinical study of AOC 1001 in adults with myotonic dystrophy type 1 (DM1)....AOC DMD is a therapeutic program in development for the treatment of Duchenne muscular dystrophy (DMD). Avidity has expanded its efforts for this indication and is now advancing three programs for DMD which target different mutations that are amenable to skipping, including Exon 44, Exon 51 and Exon 45....In 2022, Avidity plans to submit a regulatory filing to support a clinical trial."

New P1/2 trial • New trial • Duchenne Muscular Dystrophy • Myotonic Dystrophy